{"hands_on_practices": [{"introduction": "The therapeutic effect of $\\alpha_1$-blockers in BPH stems from their ability to antagonize the contractile effects of norepinephrine in prostatic smooth muscle. This exercise delves into the core principles of competitive antagonism, providing a hands-on opportunity to quantify this interaction. By applying the law of mass action to a model of receptor binding, you will calculate how an antagonist shifts the agonist's concentration-response curve, a cornerstone concept in receptor pharmacology. [@problem_id:4920153]", "problem": "A research team is characterizing competitive antagonism at the $\\alpha_{1}$-adrenergic receptor in human prostatic smooth muscle to understand drug effects relevant to Benign Prostatic Hyperplasia (BPH). In an organ bath experiment, the contractile agonist is norepinephrine ($A$), and a selective $\\alpha_{1}$ antagonist ($B$) is present at a fixed bath concentration. Assume all binding interactions obey the law of mass action, the agonist and antagonist compete reversibly for the same binding site (orthosteric competition), the system reaches equilibrium, and there are no spare receptors such that the effect at a given fraction of agonist-occupied receptors is the same whether or not the antagonist is present.\n\nLet $R$ denote free receptors, $AR$ and $BR$ denote agonist-bound and antagonist-bound receptors, respectively. The equilibrium dissociation constant for the antagonist is $K_{B}$, defined by $K_{B} = \\frac{[B][R]}{[BR]}$. The antagonist is applied at concentration $[B] = 30\\,\\mathrm{nM}$. The experimentally determined $K_{B}$ for this antagonist under these conditions is $K_{B} = 13\\,\\mathrm{nM}$.\n\nStarting from the core definitions above and using equilibrium binding considerations for a reversible, competitive antagonist, determine the fold-shift in the norepinephrine concentration–response curve (that is, the factor by which the agonist concentration must be increased to produce the same effect at any given level of response) caused by the presence of the antagonist at $[B] = 30\\,\\mathrm{nM}$. Express your answer as a dimensionless number and round to four significant figures.", "solution": "The problem requires the determination of the fold-shift in an agonist's concentration–response curve caused by a competitive antagonist. This fold-shift, also known as the concentration ratio ($CR$) or dose ratio, is the factor by which the agonist concentration must be increased to elicit the same response in the presence of the antagonist as was achieved in its absence. The problem states that the effect is directly proportional to the fraction of receptors occupied by the agonist, due to the assumption of no spare receptors. Therefore, we are looking for the ratio of agonist concentrations that yield the same fractional receptor occupancy.\n\nLet $[R_{T}]$ be the total concentration of $\\alpha_{1}$-adrenergic receptors.\nLet $[A]$ and $[B]$ be the concentrations of the agonist (norepinephrine) and antagonist, respectively.\nLet $K_{A}$ and $K_{B}$ be the equilibrium dissociation constants for the agonist and antagonist, respectively. These are defined by the law of mass action at equilibrium:\n$$K_{A} = \\frac{[A][R]}{[AR]}$$\n$$K_{B} = \\frac{[B][R]}{[BR]}$$\nwhere $[R]$ is the concentration of free receptors, $[AR]$ is the concentration of agonist-bound receptors, and $[BR]$ is the concentration of antagonist-bound receptors.\n\nThe fractional occupancy of receptors by the agonist, denoted as $p_{A}$, is given by $p_{A} = \\frac{[AR]}{[R_{T}]}$.\n\nFirst, consider the case without the antagonist ($[B]=0$). The total receptor population consists of free and agonist-bound receptors:\n$$[R_{T}] = [R] + [AR]$$\nFrom the definition of $K_{A}$, we can express $[R]$ in terms of $[AR]$: $[R] = \\frac{K_{A}[AR]}{[A]}$.\nSubstituting this into the equation for $[R_{T}]$:\n$$[R_{T}] = \\frac{K_{A}[AR]}{[A]} + [AR] = [AR]\\left(\\frac{K_{A}}{[A]} + 1\\right) = [AR]\\left(\\frac{K_{A} + [A]}{[A]}\\right)$$\nThe fractional occupancy $p_{A}$ is then:\n$$p_{A} = \\frac{[AR]}{[R_{T}]} = \\frac{[A]}{[A] + K_{A}}$$\n\nNext, consider the case in the presence of the antagonist at a fixed concentration $[B]$. Now, the total receptor population is distributed among three states: free, agonist-bound, and antagonist-bound.\n$$[R_{T}] = [R] + [AR] + [BR]$$\nUsing the definitions of $K_{A}$ and $K_{B}$, we can express $[AR]$ and $[BR]$ in terms of $[R]$:\n$$[AR] = \\frac{[A'][R]}{K_{A}}$$\n$$[BR] = \\frac{[B][R]}{K_{B}}$$\nHere, we use $[A']$ to denote the agonist concentration required to achieve a certain effect in the presence of the antagonist.\nSubstitute these into the equation for $[R_{T}]$:\n$$[R_{T}] = [R] + \\frac{[A'][R]}{K_{A}} + \\frac{[B][R]}{K_{B}} = [R]\\left(1 + \\frac{[A']}{K_{A}} + \\frac{[B]}{K_{B}}\\right)$$\nTo find the fractional occupancy, we again solve for $p_{A} = \\frac{[AR]}{[R_{T}]}$. We can express $[R]$ in terms of $[AR]$ as $[R] = \\frac{K_{A}[AR]}{[A']}$.\n$$[R_{T}] = \\frac{K_{A}[AR]}{[A']}\\left(1 + \\frac{[A']}{K_{A}} + \\frac{[B]}{K_{B}}\\right) = [AR]\\left(\\frac{K_{A}}{[A']} + 1 + \\frac{K_{A}}{[A']}\\frac{[B]}{K_{B}}\\right)$$\nThe fractional occupancy, $p'_{A}$, in the presence of the antagonist is:\n$$p'_{A} = \\frac{[AR]}{[R_{T}]} = \\frac{1}{1 + \\frac{K_{A}}{[A']}\\left(1 + \\frac{[B]}{K_{B}}\\right)} = \\frac{[A']}{[A'] + K_{A}\\left(1 + \\frac{[B]}{K_{B}}\\right)}$$\n\nThe fold-shift is the factor by which the agonist concentration must be increased to produce the same effect. Since effect is tied to fractional occupancy, we set $p_{A} = p'_{A}$:\n$$\\frac{[A]}{[A] + K_{A}} = \\frac{[A']}{[A'] + K_{A}\\left(1 + \\frac{[B]}{K_{B}}\\right)}$$\nThis equality must hold for any level of response, which implies a direct relationship between the terms. Let's rearrange the equation:\n$$[A]\\left([A'] + K_{A}\\left(1 + \\frac{[B]}{K_{B}}\\right)\\right) = [A']([A] + K_{A})$$\n$$[A][A'] + [A]K_{A}\\left(1 + \\frac{[B]}{K_{B}}\\right) = [A'][A] + [A']K_{A}$$\n$$[A]K_{A}\\left(1 + \\frac{[B]}{K_{B}}\\right) = [A']K_{A}$$\nDividing both sides by $[A]K_{A}$ (assuming $K_A \\neq 0$ and $[A] \\neq 0$ for a non-zero response):\n$$\\frac{[A']}{[A]} = 1 + \\frac{[B]}{K_{B}}$$\nThis is the celebrated Gaddum-Schild equation. The fold-shift, or concentration ratio ($CR$), is $\\frac{[A']}{[A]}$.\n\nThe problem provides the following values:\nAntagonist concentration, $[B] = 30\\,\\mathrm{nM}$\nAntagonist equilibrium dissociation constant, $K_{B} = 13\\,\\mathrm{nM}$\n\nWe can now compute the fold-shift:\n$$CR = 1 + \\frac{[B]}{K_{B}} = 1 + \\frac{30\\,\\mathrm{nM}}{13\\,\\mathrm{nM}}$$\n$$CR = 1 + \\frac{30}{13} \\approx 1 + 2.3076923...$$\n$$CR \\approx 3.3076923...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$CR \\approx 3.308$$\nThis means that in the presence of $30\\,\\mathrm{nM}$ of the antagonist, the concentration of norepinephrine must be increased by a factor of approximately $3.308$ to achieve the same level of smooth muscle contraction as in the absence of the antagonist.", "answer": "$$\\boxed{3.308}$$", "id": "4920153"}, {"introduction": "While finasteride and dutasteride are both $5\\alpha$-reductase inhibitors, their clinical profiles differ due to their distinct actions on the enzyme's two main isoenzymes. This practice provides a quantitative framework to explore the consequences of selective versus dual enzyme inhibition. Based on a hypothetical but plausible scenario with given inhibition data, you will calculate and compare the total reduction in dihydrotestosterone (DHT) caused by each drug, providing insight into why dutasteride produces a more profound suppression of systemic DHT. [@problem_id:4920217]", "problem": "A male patient with Benign Prostatic Hyperplasia (BPH) has a baseline serum concentration of Dihydrotestosterone (DHT) of $48 \\ \\text{ng/dL}$ measured at steady state. In circulation, $5\\alpha$-reductase exists as two isoenzymes: type I and type II. At baseline, the fractional contributions of type I and type II isoenzymes to total DHT production are $0.35$ and $0.65$, respectively. Assume hepatic and renal clearance mechanisms for DHT are unchanged by therapy, so that the steady-state serum concentration is directly proportional to the net production rate.\n\nPublished suppression data report the following enzyme activity reductions under standard dosing:\n- Finasteride: reduces type II $5\\alpha$-reductase activity by $0.70$ and has negligible effect on type I $5\\alpha$-reductase.\n- Dutasteride: reduces type I $5\\alpha$-reductase activity by $0.85$ and type II $5\\alpha$-reductase activity by $0.90$.\n\nUsing only these assumptions and data, derive the expected steady-state serum DHT reduction fraction for finasteride and for dutasteride. Then compute the difference between these two reduction fractions, defined as the dutasteride reduction fraction minus the finasteride reduction fraction. Express the final difference as a decimal (no percent sign), and round your answer to four significant figures.", "solution": "Let $P_{DHT,0}$ be the total baseline production rate of DHT. Let $f_I = 0.35$ and $f_{II} = 0.65$ be the fractional contributions of type I and type II isoenzymes to this total production, respectively. The baseline production rates from each isoenzyme are:\n-   $P_{I,0} = f_I \\cdot P_{DHT,0} = 0.35 \\cdot P_{DHT,0}$\n-   $P_{II,0} = f_{II} \\cdot P_{DHT,0} = 0.65 \\cdot P_{DHT,0}$\n\nThe problem states that the steady-state serum concentration is directly proportional to the net production rate. Therefore, the fractional reduction in concentration is equal to the fractional reduction in the total production rate. The total reduction fraction, $R$, is given by:\n$$R = 1 - \\frac{P_{drug}}{P_{DHT,0}}$$\nwhere $P_{drug}$ is the total production rate in the presence of the drug.\n\nAn enzyme activity reduction *by* a fraction $i$ means the residual activity is $(1-i)$. The new production rate from an inhibited isoenzyme is its baseline production rate multiplied by its residual activity factor.\n\n**1. Finasteride Therapy**\nFinasteride reduces type II activity by a fraction $i_{F,II} = 0.70$ and has no effect on type I activity ($i_{F,I} = 0$).\nThe residual activity factors are:\n-   Type I: $a_{F,I} = 1 - i_{F,I} = 1 - 0 = 1.0$\n-   Type II: $a_{F,II} = 1 - i_{F,II} = 1 - 0.70 = 0.30$\n\nThe total DHT production rate with finasteride, $P_F$, is the sum of the new rates from each isoenzyme:\n$$P_F = (a_{F,I} \\cdot P_{I,0}) + (a_{F,II} \\cdot P_{II,0})$$\n$$P_F = (1.0 \\cdot 0.35 \\cdot P_{DHT,0}) + (0.30 \\cdot 0.65 \\cdot P_{DHT,0})$$\n$$P_F = (0.35 + 0.195) \\cdot P_{DHT,0} = 0.545 \\cdot P_{DHT,0}$$\nThe fractional reduction for finasteride, $R_F$, is:\n$$R_F = 1 - \\frac{P_F}{P_{DHT,0}} = 1 - 0.545 = 0.455$$\n\n**2. Dutasteride Therapy**\nDutasteride reduces type I activity by $i_{D,I} = 0.85$ and type II activity by $i_{D,II} = 0.90$.\nThe residual activity factors are:\n-   Type I: $a_{D,I} = 1 - i_{D,I} = 1 - 0.85 = 0.15$\n-   Type II: $a_{D,II} = 1 - i_{D,II} = 1 - 0.90 = 0.10$\n\nThe total DHT production rate with dutasteride, $P_D$, is:\n$$P_D = (a_{D,I} \\cdot P_{I,0}) + (a_{D,II} \\cdot P_{II,0})$$\n$$P_D = (0.15 \\cdot 0.35 \\cdot P_{DHT,0}) + (0.10 \\cdot 0.65 \\cdot P_{DHT,0})$$\n$$P_D = (0.0525 + 0.065) \\cdot P_{DHT,0} = 0.1175 \\cdot P_{DHT,0}$$\nThe fractional reduction for dutasteride, $R_D$, is:\n$$R_D = 1 - \\frac{P_D}{P_{DHT,0}} = 1 - 0.1175 = 0.8825$$\n\n**3. Difference in Reduction Fractions**\nThe problem asks for the difference between the dutasteride and finasteride reduction fractions:\n$$\\Delta R = R_D - R_F$$\n$$\\Delta R = 0.8825 - 0.455 = 0.4275$$\nThe final answer, rounded to four significant figures, is $0.4275$.", "answer": "$$\n\\boxed{0.4275}\n$$", "id": "4920217"}, {"introduction": "Effective pharmacotherapy requires not only understanding a drug's mechanism but also how it affects clinical monitoring tools. This exercise bridges theory and practice by modeling the impact of finasteride on Prostate-Specific Antigen (PSA), a key biomarker for prostate health. You will use a first-order turnover model to predict the decline in PSA levels and, critically, apply the \"PSA doubling rule\"—a clinical heuristic essential for correctly interpreting cancer screening results in patients undergoing this therapy. [@problem_id:4920109]", "problem": "A man aged $65$ years with Benign Prostatic Hyperplasia (BPH) is started on finasteride $5\\,\\mathrm{mg}$ daily. The serum PSA time course can be modeled as a first-order biomarker turnover process with production driven by androgen receptor signaling and elimination with a constant fractional rate. Assume the following scientifically grounded base and parameters:\n\n- PSA obeys a turnover model: production rate $k_{\\mathrm{in}}$ and first-order elimination rate $k_{\\mathrm{out}}$, so that at any time $t$, $$\\frac{d\\,\\mathrm{PSA}(t)}{dt} = k_{\\mathrm{in}}\\left(1 - S(t)\\right) - k_{\\mathrm{out}}\\,\\mathrm{PSA}(t),$$ where $S(t)$ is the fractional suppression of androgen-driven PSA production at time $t$.\n- At baseline (no drug), the steady state satisfies $S(t)=0$ and $\\frac{d\\,\\mathrm{PSA}}{dt}=0$, giving $$\\mathrm{PSA}_{0} = \\frac{k_{\\mathrm{in}}}{k_{\\mathrm{out}}}.$$\n- Finasteride inhibits $5\\alpha$-reductase, reducing intraprostatic dihydrotestosterone (DHT). Take the steady-state DHT reduction fraction to be $f_{\\mathrm{DHT}} = 0.80$ (that is, DHT falls by $80\\%$ from baseline under chronic dosing). Assume PSA production sensitivity to DHT suppression is captured by a coupling coefficient $\\alpha$, so that the finasteride-induced steady-state fractional suppression of PSA production is $$S_{\\mathrm{ss}} = \\alpha\\,f_{\\mathrm{DHT}}.$$ Use $\\alpha = 0.70$.\n- The PSA elimination half-life is $t_{1/2} = 3.0\\,\\mathrm{days}$, so $k_{\\mathrm{out}} = (\\ln 2)/t_{1/2}$.\n- The patient’s baseline steady-state PSA is $\\mathrm{PSA}_{0} = 6.0\\,\\mathrm{ng\\cdot mL^{-1}}$.\n- After initiating finasteride, $S(t)$ rapidly reaches $S_{\\mathrm{ss}}$ compared to PSA elimination dynamics, so you may treat $S(t) = S_{\\mathrm{ss}}$ as constant for $t \\ge 0$.\n\nStarting from these fundamentals, derive the time course solution for $\\mathrm{PSA}(t)$ under a step-change in suppression from $S=0$ to $S=S_{\\mathrm{ss}}$ at $t=0$. Then, at $t=180\\,\\mathrm{days}$, compute:\n1. The expected percentage reduction in PSA relative to baseline, expressed as a decimal fraction (unitless).\n2. The “adjusted PSA” obtained by applying the clinical “PSA doubling rule” used for cancer screening in patients taking $5\\alpha$-reductase inhibitors, defined as $2\\times \\mathrm{PSA}(t)$, expressed in $\\mathrm{ng\\cdot mL^{-1}}$. Determine whether this adjusted value exceeds the commonly used referral threshold of $4.0\\,\\mathrm{ng\\cdot mL^{-1}}$ (the interpretation will be verbal in your reasoning, but the computed adjusted PSA must be reported numerically).\n\nRound both computed quantities to four significant figures. Express the adjusted PSA in $\\mathrm{ng\\cdot mL^{-1}}$. Express the percentage reduction as a decimal or fraction, not with a percentage sign.", "solution": "The problem statement has been validated and found to be scientifically grounded, well-posed, and objective. It provides a clear, quantitative framework based on established principles of pharmacodynamic biomarker modeling. All necessary data and conditions for a unique solution are provided, and there are no internal contradictions or scientifically implausible assumptions.\n\nThe time course of Prostate-Specific Antigen (PSA) is described by the first-order turnover model:\n$$\n\\frac{d\\,\\mathrm{PSA}(t)}{dt} = k_{\\mathrm{in}}\\left(1 - S(t)\\right) - k_{\\mathrm{out}}\\,\\mathrm{PSA}(t)\n$$\nwhere $k_{\\mathrm{in}}$ is the production rate, $k_{\\mathrm{out}}$ is the first-order elimination rate constant, and $S(t)$ is the fractional suppression of PSA production.\n\nAt baseline ($t<0$), the system is at steady state with no drug-induced suppression, so $S(t)=0$ and $\\frac{d\\,\\mathrm{PSA}}{dt}=0$. This gives the baseline PSA, $\\mathrm{PSA}_0$, as:\n$$\n0 = k_{\\mathrm{in}}(1-0) - k_{\\mathrm{out}}\\,\\mathrm{PSA}_{0} \\implies \\mathrm{PSA}_{0} = \\frac{k_{\\mathrm{in}}}{k_{\\mathrm{out}}}\n$$\nThe problem states the patient's baseline PSA is $\\mathrm{PSA}_{0} = 6.0\\,\\mathrm{ng\\cdot mL^{-1}}$.\n\nFinasteride treatment is initiated at $t=0$. The problem states that the suppression of PSA production rapidly reaches a new steady-state value, $S_{\\mathrm{ss}}$, which can be treated as constant for $t \\ge 0$. This suppression is given by:\n$$\nS_{\\mathrm{ss}} = \\alpha\\,f_{\\mathrm{DHT}}\n$$\nUsing the provided values $\\alpha = 0.70$ and $f_{\\mathrm{DHT}} = 0.80$:\n$$\nS_{\\mathrm{ss}} = 0.70 \\times 0.80 = 0.56\n$$\nThe PSA elimination half-life is $t_{1/2} = 3.0\\,\\mathrm{days}$. The elimination rate constant $k_{\\mathrm{out}}$ is related to the half-life by:\n$$\nk_{\\mathrm{out}} = \\frac{\\ln 2}{t_{1/2}} = \\frac{\\ln 2}{3.0}\\,\\mathrm{days^{-1}}\n$$\nFor $t \\ge 0$, the differential equation governing $\\mathrm{PSA}(t)$ becomes:\n$$\n\\frac{d\\,\\mathrm{PSA}(t)}{dt} = k_{\\mathrm{in}}\\left(1 - S_{\\mathrm{ss}}\\right) - k_{\\mathrm{out}}\\,\\mathrm{PSA}(t)\n$$\nThis is a linear first-order ordinary differential equation. We can rearrange it into standard form:\n$$\n\\frac{d\\,\\mathrm{PSA}(t)}{dt} + k_{\\mathrm{out}}\\,\\mathrm{PSA}(t) = k_{\\mathrm{in}}\\left(1 - S_{\\mathrm{ss}}\\right)\n$$\nThe general solution to this equation is the sum of the particular solution (the new steady state) and the homogeneous solution. The new steady-state PSA, which we denote $\\mathrm{PSA}_{\\mathrm{ss}}$, is found by setting $\\frac{d\\,\\mathrm{PSA}}{dt}=0$:\n$$\n\\mathrm{PSA}_{\\mathrm{ss}} = \\frac{k_{\\mathrm{in}}(1-S_{\\mathrm{ss}})}{k_{\\mathrm{out}}} = \\left(\\frac{k_{\\mathrm{in}}}{k_{\\mathrm{out}}}\\right)(1-S_{\\mathrm{ss}}) = \\mathrm{PSA}_{0}(1-S_{\\mathrm{ss}})\n$$\nThe general solution is of the form:\n$$\n\\mathrm{PSA}(t) = \\mathrm{PSA}_{\\mathrm{ss}} + C\\exp(-k_{\\mathrm{out}}t) = \\mathrm{PSA}_{0}(1-S_{\\mathrm{ss}}) + C\\exp(-k_{\\mathrm{out}}t)\n$$\nwhere $C$ is a constant of integration determined by the initial condition. At $t=0$, the PSA level is still at its baseline value, so $\\mathrm{PSA}(0) = \\mathrm{PSA}_0$.\n$$\n\\mathrm{PSA}(0) = \\mathrm{PSA}_{0}(1-S_{\\mathrm{ss}}) + C\\exp(0) \\implies \\mathrm{PSA}_{0} = \\mathrm{PSA}_{0} - \\mathrm{PSA}_{0}S_{\\mathrm{ss}} + C\n$$\nSolving for $C$ gives $C = \\mathrm{PSA}_{0}S_{\\mathrm{ss}}$.\nSubstituting $C$ back into the general solution yields the specific solution for the time course of PSA under finasteride treatment:\n$$\n\\mathrm{PSA}(t) = \\mathrm{PSA}_{0}(1-S_{\\mathrm{ss}}) + \\mathrm{PSA}_{0}S_{\\mathrm{ss}}\\exp(-k_{\\mathrm{out}}t)\n$$\n$$\n\\mathrm{PSA}(t) = \\mathrm{PSA}_{0} \\left[ (1-S_{\\mathrm{ss}}) + S_{\\mathrm{ss}}\\exp(-k_{\\mathrm{out}}t) \\right]\n$$\nWe need to compute the required quantities at $t = 180\\,\\mathrm{days}$. First, we evaluate the exponential term's argument:\n$$\n-k_{\\mathrm{out}}t = -\\left(\\frac{\\ln 2}{3.0\\,\\mathrm{days}}\\right) \\times (180\\,\\mathrm{days}) = -60\\ln 2\n$$\nThe exponential term is therefore:\n$$\n\\exp(-60\\ln 2) = \\exp(\\ln(2^{-60})) = 2^{-60}\n$$\nThe value of $2^{-60}$ is approximately $8.67 \\times 10^{-19}$, which is extraordinarily small and can be considered negligible for the purpose of calculating values to four significant figures. The system has effectively reached its new steady state after $180\\,\\mathrm{days}$ (which is $60$ PSA half-lives).\n\nThus, we can approximate $\\mathrm{PSA}(180)$ as the new steady-state value:\n$$\n\\mathrm{PSA}(180) \\approx \\mathrm{PSA}_{\\mathrm{ss}} = \\mathrm{PSA}_{0}(1-S_{\\mathrm{ss}})\n$$\nSubstituting the numerical values:\n$$\n\\mathrm{PSA}(180) = (6.0\\,\\mathrm{ng\\cdot mL^{-1}}) \\times (1 - 0.56) = (6.0\\,\\mathrm{ng\\cdot mL^{-1}}) \\times 0.44 = 2.64\\,\\mathrm{ng\\cdot mL^{-1}}\n$$\nTo four significant figures, this is $2.640\\,\\mathrm{ng\\cdot mL^{-1}}$.\n\nNow, we compute the two requested quantities.\n\n1. The expected percentage reduction in PSA relative to baseline, expressed as a decimal fraction.\nThe reduction fraction, $R(t)$, is given by:\n$$\nR(t) = \\frac{\\mathrm{PSA}_{0} - \\mathrm{PSA}(t)}{\\mathrm{PSA}_{0}} = 1 - \\frac{\\mathrm{PSA}(t)}{\\mathrm{PSA}_{0}}\n$$\nSubstituting the expression for $\\mathrm{PSA}(t)$:\n$$\nR(t) = 1 - \\left[ (1-S_{\\mathrm{ss}}) + S_{\\mathrm{ss}}\\exp(-k_{\\mathrm{out}}t) \\right] = S_{\\mathrm{ss}} - S_{\\mathrm{ss}}\\exp(-k_{\\mathrm{out}}t) = S_{\\mathrm{ss}}\\left(1 - \\exp(-k_{\\mathrm{out}}t)\\right)\n$$\nAt $t = 180\\,\\mathrm{days}$:\n$$\nR(180) = 0.56 \\times (1 - \\exp(-60\\ln 2)) = 0.56 \\times (1 - 2^{-60})\n$$\nSince $2^{-60}$ is negligibly small, $(1 - 2^{-60})$ is practically equal to $1$. The reduction is effectively equal to the steady-state suppression $S_{\\mathrm{ss}}$.\n$$\nR(180) \\approx 0.56\n$$\nRounding to four significant figures, the reduction is $0.5600$.\n\n2. The “adjusted PSA” obtained by applying the clinical “PSA doubling rule”.\nThe adjusted PSA is defined as $2 \\times \\mathrm{PSA}(t)$. At $t=180\\,\\mathrm{days}$:\n$$\n\\mathrm{Adjusted\\ PSA} = 2 \\times \\mathrm{PSA}(180) = 2 \\times 2.640\\,\\mathrm{ng\\cdot mL^{-1}} = 5.280\\,\\mathrm{ng\\cdot mL^{-1}}\n$$\nThis value must be compared to the referral threshold of $4.0\\,\\mathrm{ng\\cdot mL^{-1}}$.\n$$\n5.280\\,\\mathrm{ng\\cdot mL^{-1}} > 4.0\\,\\mathrm{ng\\cdot mL^{-1}}\n$$\nThe patient’s adjusted PSA value at $180$ days exceeds the common referral threshold, which would typically warrant further investigation for prostate cancer, despite the observed PSA decrease from baseline. The \"doubling rule\" is a clinical heuristic to account for the PSA-lowering effect of the drug when screening for cancer.\n\nFinal computed values rounded to four significant figures are:\n- Percentage reduction (decimal fraction): $0.5600$\n- Adjusted PSA: $5.280\\,\\mathrm{ng\\cdot mL^{-1}}$", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.5600 & 5.280 \\end{pmatrix}}\n$$", "id": "4920109"}]}